Investing.com - Cantor Fitzgerald重申了对 Belite Bio, Inc, ADR (NASDAQ:BLTE) 的"增持"评级，维持了对这家开发斯塔加特病治疗方案公司的积极展望。根据 InvestingPro 数据，该股票表现出显著的增长势头，过去六个月上涨了141%，过去一年上涨了182%。

Investing.com - Cantor Fitzgerald在 Cabaletta Bio Inc. (NASDAQ:CABA) 的Cellares制造方法获得IND许可后，重申了对该公司的"增持"评级。这一看涨立场与分析师的普遍共识一致，根据 InvestingPro 数据显示，尽管该股票交易价格远低于分析师30美元的最高目标价，但仍保持强烈的正面评级，评分为1.5。

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for ...

Fintel reports that on October 31, 2025, Cantor Fitzgerald maintained coverage of Cabaletta Bio (NasdaqGS:CABA) with a Overweight recommendation. As of October 30, 2025, the average one-year price ...

Fintel reports that on April 29, 2025, Cantor Fitzgerald initiated coverage of Korro Bio (NasdaqCM:KRRO) with a Overweight recommendation. As of April 24, 2025, the average one-year price target for ...

Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) – Investment analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for Gossamer Bio in a report issued on Monday, March 24th. Cantor ...